drugset / Trial / NCT04429152
ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance
Timeline
- Start
- 2021-02-09
- Primary completion
- 2023-09
- Completion
- 2023-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doravirine | Small molecule | 100 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | — |